Slide 1: CT1812 for Alzheimer's Disease: Focusing on the Lower p-tau217 Subgroup
CT1812 for Alzheimer's Disease Focusing on the Lower p-tau217 Subgroup October 30, 2024
Slide 2: Forward-looking Statements
Forward-looking Statements FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate t
Slide 3: CT1812 Mechanism of Action
CT1812 Mechanism of Action Investigational, oral, small molecule oligomer antagonist Aβ oligomers • Preclinical and clinical evidence that CT1812 Small Molecule CT1812 acts to displace Aβ oligomers from synapses, facilitating clearance of Aβ oligomers in the cerebrospinal fluid (CSF) PrPc LilrB2 TME
Slide 4: Phase 2 PoC Study in Mild-to-Moderate Alzheimer's Disease
Phase 2 PoC Study in Mild-to-Moderate Alzheimer’s Disease Included prespecified analysis in participants with baseline plasma p-tau217 above and below median Select Inclusion and Treatment Period Key Objectives Exclusion 6 months • AD diagnosis confirmed by • Safety/tolerability CT1812 300 mg PET or
Slide 5: Tau Burden in Amyloid-related AD Clinical Trials
Tau Burden in Amyloid-related AD Clinical Trials Plasma p-tau217: prognostic biomarker of response to therapy • Plasma p-tau217 reflects brain amyloid and tau burden • Prior data indicate that individuals with lower AD pathology, as reflected by lower plasma p-tau217, have greater response to amyloi
Slide 6: Baseline Characteristics of Below/Above median p-tau217
Baseline Characteristics of Below/Above median p-tau217 Reflects expected baseline characteristics based on mITT population Below median* Above or equal to median* mITT population (n=150) p-tau217 Cohort (n=69) p-tau217 Cohort (n=69) Percent (%) female 60 59.4 58 Percent (%) white 96 94.2 97.1 Perce
Slide 7: Summary of SHINE Safety and Tolerability findings
Summary of SHINE Safety and Tolerability findings Full safety data presented at AAIC '24 showing favorable profile with most TEAEs mild or moderate • CT1812 demonstrated a generally favorable safety and Adverse Events tolerability profile CT1812 Placebo • Most treatment emergent adverse events (TEAE
Slide 8: Impact of Plasma p-tau217
Impact of Plasma p-tau217 Cognition and Function
Slide 9: SHINE Cognitive Endpoints: ADAS-Cog 11
SHINE Cognitive Endpoints: ADAS-Cog 11 Preservation of ADAS-Cog 11 in participants below median plasma p-tau217† mITT population* (n=150) Below median p-tau217 (n=69) Above median p-tau217 (n=69) * ADAS-Cog 11 mITT in the pooled dose group vs placebo was the first of the ordered secondary efficacy e
Slide 10: SHINE Cognitive Endpoints: MMSE
SHINE Cognitive Endpoints: MMSE Preservation of MMSE in participants below median plasma p-tau217* mITT population (n=150) Below median p-tau217 (n=69) 10 * Median plasma p-tau217 level is 1.0pg/mL at baseline
Slide 11: SHINE Functional Endpoints: ADCS-ADL and -CGIC
SHINE Functional Endpoints: ADCS-ADL and -CGIC Function and global impression preserved in participants below median plasma p-tau217* ADCS-ADL ADCS-CGIC Below median plasma p-tau217 (n=69) Below median plasma p-tau217 (n=69) 11 * Median plasma p-tau217 level is 1.0pg/mL at baseline
Slide 12: Anton Porsteinsson, MD
Anton Porsteinsson, MD University of Rochester Alzheimer's Disease Care, Research and Education Program
Slide 13: CT1812 SHINE Study: Summary and Conclusions
CT1812 SHINE Study: Summary and Conclusions Plasma p-tau217 biomarker identifies strong CT1812-treatment responder group • CT1812 generally safe and well tolerated Additional SHINE data: • mITT showed favorable trends in CT1812-treated participants Results from COG0201 Vijverberg et al. AAIC 2024 •
Slide 14: Cognition Snapshot
Cognition Snapshot Successful Phase 2 AD trial read out plus signal-finding studies ongoing in other indications Alzheimer’s Dementia with Lewy Geographic Atrophy Disease Bodies (DLB) Secondary to dry AMD • Pursuing 2 populations: mild-to- • Phase 2 signal-finding SHIMMER • Phase 2 signal-finding MA
Slide 15: Thank You
Thank You Lisa Ricciardi President & CEO lricciardi@cogrx.com Tony Caggiano, MD, PhD CMO and Head of R&D acaggiano@cogrx.com John Doyle Chief Financial Officer jdoyle@cogrx.com